Global Hepatitis B Vaccination Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hepatitis B Vaccination Market Research Report 2024
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.
According to Mr Accuracy reports new survey, global Hepatitis B Vaccination market is projected to reach US$ 1179.8 million in 2029, increasing from US$ 1063 million in 2022, with the CAGR of 1.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hepatitis B Vaccination market research.
The hepatitis B vaccination market is driven by the increasing focus on disease prevention and the rising awareness of the importance of immunization. Hepatitis B vaccines provide essential protection against the hepatitis B virus (HBV), which can cause chronic liver infections and increase the risk of liver cirrhosis and cancer. The rise in the prevalence of hepatitis B infections and the need for effective control of the disease contribute to market growth as vaccination plays a crucial role in reducing transmission and preventing complications. Moreover, advancements in vaccine technology, such as the development of combination vaccines and birth dose administration, have improved vaccine accessibility and coverage. However, the market also faces challenges, including vaccine supply limitations and the need for ongoing public health initiatives to address barriers to vaccination, such as vaccine hesitancy and lack of awareness. Additionally, ensuring equitable access to hepatitis B vaccines and increasing vaccination rates in high-risk populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable hepatitis B vaccines, collaborate with healthcare providers and governments to implement vaccination programs, and address the challenges to meet the increasing demand for effective and accessible protection against hepatitis B.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hepatitis B Vaccination market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute
Segment by Type
Yeast Derived
CHO Derived
Children
Adult
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hepatitis B Vaccination report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Hepatitis B Vaccination market is projected to reach US$ 1179.8 million in 2029, increasing from US$ 1063 million in 2022, with the CAGR of 1.5% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hepatitis B Vaccination market research.
The hepatitis B vaccination market is driven by the increasing focus on disease prevention and the rising awareness of the importance of immunization. Hepatitis B vaccines provide essential protection against the hepatitis B virus (HBV), which can cause chronic liver infections and increase the risk of liver cirrhosis and cancer. The rise in the prevalence of hepatitis B infections and the need for effective control of the disease contribute to market growth as vaccination plays a crucial role in reducing transmission and preventing complications. Moreover, advancements in vaccine technology, such as the development of combination vaccines and birth dose administration, have improved vaccine accessibility and coverage. However, the market also faces challenges, including vaccine supply limitations and the need for ongoing public health initiatives to address barriers to vaccination, such as vaccine hesitancy and lack of awareness. Additionally, ensuring equitable access to hepatitis B vaccines and increasing vaccination rates in high-risk populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable hepatitis B vaccines, collaborate with healthcare providers and governments to implement vaccination programs, and address the challenges to meet the increasing demand for effective and accessible protection against hepatitis B.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hepatitis B Vaccination market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute
Segment by Type
Yeast Derived
CHO Derived
Segment by Application
Children
Adult
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hepatitis B Vaccination report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices